(secondQuint)Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis.

 This is a Phase 1/2, open-label study designed to evaluate the safety, tolerability and procedure of a microneedle injection of triamcinolone acetonide (TA) into the SCS.

 The subjects enrolled in this study will be chosen from subjects with non-infectious intermediate, posterior and pan-uveitis.

 The injection will only be administered to a single eye via the Clearside Biomedical proprietary microneedle into the SCS.

 The dose of TA to be injected is 4 mg of currently approved TRIESENCE(R) (triamcinolone acetonide injectable suspension 40 mg/mL).

 The study design includes 10 clinic visits over 27 weeks.

 Subjects will be followed for 26 weeks following treatment with TRIESENCE(R).

.

 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis@highlight

This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE(R)) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.

